Needham reiterated coverage of Alcon with a rating of Buy and set a new price target of $108.00 from $103.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Hold | Deutsche Bank | |
| 5/14/2025 | $102.00 → $99.00 | Buy | BTIG Research |
| 3/28/2025 | $107.00 → $110.00 | Buy | Needham |
| 3/25/2025 | Neutral → Buy | BofA Securities | |
| 1/24/2025 | $108.00 → $106.00 | Buy | Needham |
| 1/10/2025 | Neutral → Buy | Redburn Atlantic | |
| 12/17/2024 | $103.00 → $108.00 | Buy | Needham |
Analyst downgraded Alcon from Overweight to Neutral
Deutsche Bank downgraded Alcon from Buy to Hold
BTIG Research reiterated coverage of Alcon with a rating of Buy and set a new price target of $99.00 from $102.00 previously
Raises Concerns About Whether the Board Fulfilled Its Fiduciary Duty of Care in Doubling Down on Its Commitment to Proposed Transaction Renewed Support Comes After Stunning Revelation STAAR CEO and Chair Failed to Disclose Inbound Interest in Acquiring the Company to Rest of Board Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today issued the following letter to the Board of Directors (the "Board") of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Broadwood, which owns 27.5% of STAAR's outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN Proxy Card "AGAINST" the proposed acquisition of STAAR by Alcon Inc. (
Comments on Glass Lewis Report STAAR Surgical Company (NASDAQ:STAA) ("STAAR"), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today provided the following statement in response to a report issued by Glass, Lewis & Co., LLC ("Glass Lewis") related to STAAR's pending merger with Alcon (SIX/NYSE:ALC): The STAAR Board of Directors and management team strongly disagree with the recommendation issued by Glass Lewis. Alcon is paying STAAR stockholders a 59% premium to the 90-day VWAP, whereas Broadwood's proposal to vote down the merger could allow Broadwood to take control without paying any premium to other stockholders.
Glass Lewis Highlights Numerous Concerns Regarding the Sale Process, Timing, and Price Confirms CEO and Chair Did Not Disclose Information to the Rest of the Board About Inbound Interest in Acquiring the Company Finds STAAR Shareholders Would Be Better Served by Rejecting the Proposed Merger Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we") today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, has recommended that the shareholders of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) vote "AGAINST" the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE:ALC) on the terms announced on August 5, 2025
DEFM14A - ALCON INC (0001167379) (Filer)
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the US Announced agreement to acquire STAAR Surgical, expanding Alcon's presence in myopia correction Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month
STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d
First-quarter 2025 sales of $2.5 billion, in line on a reported basis, or up 3% constant currency1 (cc), versus first-quarter 2024 First-quarter 2025 diluted EPS of $0.70; core diluted EPS2 of $0.73 Generated $384 million cash from operations and $278 million free cash flow3 Dividend of CHF 0.28 per share approved by shareholders at the Annual General Meeting on May 6, 2025 Launched rich pipeline of innovative products, including Voyager, Precision7 and Systane Pro PF in Q1 2025; Unity VCS and PanOptix Pro in May 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)